PBAC's latest decision on Telmisartan with amlodipine: Recommended with restriction (2011). Considered for Hypertension in a patient who is not adequately controlled with either of the drugs in the combination.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2011
Submissions
1
2011 → 2011
Eligible population
patients who have trialled and failed monotherapy with either telmisartan or amlodipine
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
DBP
Key trials
BI 1235.5, BI 1235.6, BI 1235.13, BI 1235.14
Comparator
telmisartan and amlodipine as monotherapies (individual equivalent strengths administered separately)
Economic model
Cost-minimisation
Budget impact
$9M
ICER note
Cost-minimisation analysis performed; no ICER calculated